The purpose of this study is to test whether SU011248 has activity and is safe in patients with Renal Cell Carcinoma (RCC) and who have failed prior therapy with bevacizumab (Avastin).

Ages Eligible for Study:  18 Years and above,  Genders Eligible for Study:  Both

Criteria

• Histologically proven renal cell carcinoma of clear cell histology with metastases. RCC of papillary, collecting duct or chromophobe type without clear cell component is not permitted. In addition, transitional cell carcinoma of the renal pelvis is not allowed.
• Evidence of measurable disease by radiographic technique
• Radiographic evidence of disease progression during or within 3 months of completion of bevacizumab-based treatment
• Prior radical or partial nephrectomy
• Male or female, 18 years or older
• ECOG performace status of 0 or 1
• Resolution of all acute toxicitites of prior therapies
• Adequate organ function
• No prior treatment with any other anti-angiogenic therapy other than bevacizumab
• No prior systemic treatment for RCC > 2 regimens
• No prior surgery, radiation, or systemic therapy within 4 weeks
• No diagnosis of a second malignancy within the last 3 years
• No known brain metastases, spinal cord compression or carcinomatous meningitis
• No known HIV or AIDS-related illness
• No serious acute or chronic illness or recent history of significant cardiac abnormality
• No uncontrolled hypertension